RxDoctor Payments Data

Daphnee Pierre Louis

Family · Hamtramck, MINPI 1043612997

Payments from drug & device makers

$666in general payments, 2019–2025

Across 27 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$164
  • AbbVie$109
  • Johnson & Johnson$98
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$89
  • E.r. Squibb & Sons, L.L.C.$59
  • Alkermes, Inc.$56
  • plus $92 from 3 others

What the payments were for

  • Food & beverage$61993%
  • Education$477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$666 in reported general payments places this provider in the 60th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$10,879
Medicare patients
35
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate94$225,496
Abilify MaintenaAripiprazole35$94,021
VraylarCariprazine Hcl31$42,290
VivitrolNaltrexone Microspheres21$37,094
AustedoDeutetrabenazine13$28,995
Paliperidone ErPaliperidone128$17,145
Lurasidone Hcl67$7,810
Aripiprazole195$3,938
Clozapine62$3,119
Olanzapine OdtOlanzapine12$2,847
Atomoxetine Hcl45$2,421
Haloperidol Decanoate66$2,295
Bupropion XlBupropion Hcl161$2,234
Fluphenazine Hcl32$2,164
Buspirone Hcl127$2,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$98$225,49694 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$164$94,02135 claims
AbbVieVraylar$109$42,29031 claims
Alkermes, Inc.Vivitrol$56$37,09421 claims
Teva Pharmaceuticals USA, Inc.Austedo$41$28,99513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,657 family providers in Michigan.

Other family in Hamtramck

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →